NCT07602504 China Metastatic Liver Cancer Clinical Registry Cohort Database
| NCT ID | NCT07602504 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anhui Provincial Hospital |
| Condition | Liver Metastases |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2031-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2026-06-01 with a primary completion date of 2031-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Eligibility Criteria
Inclusion Criteria: 1. Patients with histologically or radiologically confirmed metastatic liver cancer. 2. Age ≥ 18 years. 3. Patients who have voluntarily signed the informed consent form. 4. Patients with complete baseline clinical data. Exclusion Criteria: 1. Patients with primary liver cancer (e.g., hepatocellular carcinoma). 2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis. 3. Patients who have previously participated in other interventional clinical trials. 4. Patients with severe cognitive disorders or communication barriers that prevent informed consent. 5. Patients with incomplete or missing key clinical data.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07602504 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Liver Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07602504 currently recruiting?
Yes, NCT07602504 is actively recruiting participants. Contact the research team at wangjoe@ustc.edu.cn for enrollment information.
Where is the NCT07602504 trial being conducted?
This trial is being conducted at Bengbu, China, Hefei, China, Qingdao, China.
Who is sponsoring the NCT07602504 clinical trial?
NCT07602504 is sponsored by Anhui Provincial Hospital. The trial plans to enroll 2,000 participants.